Malta - English - Medicines Authority

panpharma z.i. du clairay, 35133 luitre, france - dexamethasone sodium, phosphate - solution for injection - dexamethasone sodium phosphate 6 mg - corticosteroids for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

as kalceks - dexamethasone sodium phosphate - solution for injection/infusion - dexamethasone

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - dexamethasone sodium phosphate - solution for injection - dexamethasone

Ireland - English - HPRA (Health Products Regulatory Authority)

activase pharmaceuticals limited - dexamethasone - tablet - dexamethasone

Ireland - English - HPRA (Health Products Regulatory Authority)

activase pharmaceuticals limited - dexamethasone - tablet - dexamethasone

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - dexamethasone sodium phosphate - solution for injection - dexamethasone

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 10 mg in 1 ml - 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis synovitis of osteoarthritis rheumatoid

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 4 mg in 1 ml - intravenous or intramuscular injection when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • endocrine disorders      primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)      acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)      preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful      shock unresponsive to conventional therapy if adrenocortical insufficiency exists or

United States - English - NLM (National Library of Medicine)

direct rx - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - dexamethasone 1 mg in 1 g - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitises is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drugs in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilusinfluenzae, klebsiella/enterobacterspec

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - dexamethasone 1 mg in 1 g - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitises is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drugs in this product is active against the following common bacterial eye pathogens: staphylococcus aureus , escherichia coli, haemophilus influenzae , klebsiella / enterob